Myopia gets worse when the eyeball grows too long from front to back. Research suggests that where peripheral light comes to focus can influence that growth: in a nearsighted eye, ordinary lenses often focus the peripheral image behind the retina, which may signal the eye to keep elongating.
Peripheral-defocus myopia lenses — the category Euclid BeFree belongs to — keep the central vision clear while reshaping the peripheral optics to bring that off-axis light in front of the retina. That shift is thought to create a braking cue that slows elongation. It’s the same underlying principle behind several treatments Dr. Patel already offers, including MiSight 1 Day and Stellest spectacle lenses.
Important: Euclid BeFree is not FDA-approved for myopia control in the United States. This information is educational and is not a recommendation or an offer to provide a non-approved device. Any myopia-management decision is made individually with Dr. Patel based on your child’s exam and the treatments appropriate and available to them.
Understanding the Option
Clear central vision with peripheral optics engineered to create the myopic-defocus cue linked to slower eye growth.
Worn as a soft lens for daytime vision — familiar and comfortable for children who prefer contacts to glasses.
Offered in select markets abroad; not cleared by the FDA for myopia control in the United States.
Euclid Systems is well known for orthokeratology; BeFree extends that expertise into soft peripheral-defocus lenses.
Uses the peripheral-defocus principle already validated in FDA-cleared options like MiSight and Stellest.
A statewide myopia-control lecturer who tracks the global landscape and keeps your family informed of what’s emerging.
Book a consultation with Dr. Patel to review the full myopia-control landscape — proven treatments available now and emerging technologies like Euclid BeFree.
Frequently Asked Questions
Euclid BeFree is a soft myopia-management contact lens from Euclid Systems, a company long known for its orthokeratology lenses. BeFree uses a peripheral-defocus optical design: while the center of the lens corrects your child’s distance vision, the surrounding zones are shaped to focus peripheral light in a way intended to slow the elongation of the eye that causes worsening nearsightedness.
No. Euclid BeFree is not FDA-approved for myopia control in the United States. It is available in certain international markets. We present it here for educational purposes so families understand how peripheral-defocus soft lenses work and where the technology is headed. For treatment today, Dr. Patel recommends options with U.S. regulatory clearance and established clinical evidence.
In a nearsighted eye, standard lenses can focus peripheral light behind the retina, which some research suggests may signal the eye to keep growing longer. Peripheral-defocus myopia-management lenses are designed to move that peripheral focus in front of the retina, creating a cue thought to slow axial elongation. Several of the proven treatments Dr. Patel already offers — including MiSight and Stellest — use variations of this same peripheral-defocus principle.
PersonalEyes offers a full range of established treatments: MiSight 1 Day soft lenses (FDA-approved), orthokeratology (overnight lenses), Stellest spectacle lenses, and low-dose atropine drops. Dr. Patel measures your child’s axial length and progression risk, then recommends the option best suited to your child — and monitors emerging technologies like BeFree so your family stays informed.
Yes. Every child’s eyes and lifestyle are different, and myopia management is highly individualized. Book a consultation and Dr. Patel will review the full landscape — including where non-FDA-approved options like BeFree fit — and build a plan around the treatments that are appropriate and available for your child.